Amgen’s bispecific antibody shows high response rate in multiple myeloma at ASCO
It remains unclear how many patients will relapse without the BCMA antigen, which would complicate their ability to use many CAR-T cell therapies later on. However, an expert said the drug's safety could be a challenge.